Bromodomain inhibitors in autoimmune diseases

Autoimmune diseases are very common worldwide. The immune system becomes dysregulated in a pro-inflammatory direction. Bromodomains play a crucial role in the regulation of many inflammatory pathways, including mitogen-activated protein kinase, nuclear factor kappa B, and interleukins. Bromodomain inhibitors could allow for better autoimmune disease control and reduction of symptom severity than currently available treatment due to their direct integration into the epigenetic mechanism. This review focuses on drugs currently being tested and how their mechanisms of action are beneficial in treatment of rheumatoid arthritis, osteoarthritis, fibrosis, cirrhosis, lupus, inflammatory bowel disease. The aim of this review is show Bromodomain inhibitors as a new possible treatment strategy for a variety of autoimmune diseases. The study was conducted by selecting articles from the PubMed database published between 2011 and 2026; for some studies describing the basic pathophysiology of the diseases, this period was extended to 2002.